Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Gomes, Marilia Brito ^a   Negrato, Carlos Antonio ^b  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Bauru's Diabetics Association   (Brazil)

Author keywords

Alpha lipoic acid; Biochemical action; Chronic diseases; Diabetes mellitus

Indexed keywords

ADENOSINE KINASE; ADENOSINE MONOPHOSPHATASE PROTEIN KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; THIOCTIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AEROBIC METABOLISM; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN DISEASE; BRONCHITIS; BURNING MOUTH SYNDROME; CARDIOVASCULAR DISEASE; CHELATION; CHRONIC DISEASE; COGNITIVE DEFECT; DIABETES MELLITUS; DIABETIC CARDIOVASCULAR NEUROPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG SYNTHESIS; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; HUMAN; NAUSEA AND VOMITING; NEOPLASM; NONALCOHOLIC FATTY LIVER; OBESITY; PRURITUS; SIGNAL TRANSDUCTION; SKIN ULCER; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 84904774071     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-80     Document Type: Article

References (166)

1. Diabetes and alpha lipoic Acid. Golbidi S, Badran M, Laher I, Front Pharmacol 2011 2 69
2. From lipoic acid to multi-enzyme complexes. Reed LJ, Protein Sci 1998 7 1 220 224
3. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM, Biochim Biophys Acta 2009 1790 10 1149 1160
4. Growth factor for bacteria.VI Fractionation and properties of an accessory factor for lactic acid bacteria. Snell EE, Strong FM, Peterson WH, Bichem J 1937 31 1789 1799
5. Cristalline alpha-lipoic acid: a catalytic agent associated with pyruvate dehydrogenase. Reed LJ, De Busk BG, Gunsalus IC, Hornberger CS, Science 1951 114 93 94
6. Ein Beitrag zur Therapie der neuropathia diabetic. Bock E, Schneeweiss J, Munchner Med Wochenschrift 1959 43 1911 1912
7. Acute reversal of endothelial dysfunction in the elderly following antioxidant consumption. Wray DW, Nishyyama SK, Harris RA, Zhao J, McDaniel J, Fjeldstad AS, Witman MA, Ives SJ, Barrett-O'Keefe Z, Richardson RS, Hypertension 2012 59 818 824
8. Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance. McNeilly AM, Davison GW, Murphy MH, Nadeem N, Trinick T, Duly E, Novials A, McEneny J, Lipids Health Dis 2011 10 217
9. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice. Zhang WJ, Bird KE, McMillen TS, LeBoeuf RC, Hagen TM, Frei B, Circulation 2008 117 3 421 428
10. Lipoic acid effects on established atherosclerosis. Ying Z, Kherada N, Farrar B, Kampfrath T, Chung Y, Simonetti O, Deiuliis J, Desikan R, Khan B, Villamena F, Sun Q, Parthasarathy S, Rajagopalan S, Life Sci 2010 86 3-4 95 102
11. α Lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Ziegler D, Reljanovic M, Mehnert H, Gries FA, Exp Clin Endocrinol Diabetes 1999 107 421 430
12. Molecular aspects of lipoic acid in the prevention of diabetes complications. Packer L, Kraemer K, Rimbach G, Nutrition 2001 17 888 895
13. Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V, J Hypertens 2000 18 5 567 573
14. Lipoic acidi and n-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. Moreira PI, Harris PLR, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G, J Alzheimers Dis 2007 12 195 206
15. Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Lott IT, Doran E, Nguyen VQ, Tournay A, Head E, Gillen DL, Am J Med Genet A 2011 155A 1939 1948
16. Alfa-lipoic acid controls tumor growth and modulates hepatic redox state in Ehrlich-ascites-carcinoma-bearing mice. Al Abdan M, Scientific World Journal 2012 2012 509838
17. Quantum-chemical investigation of the structure and the antioxidant properties of α-lipoic acid and its metabolites. Szelag M, Mikulski D, Molski M, J Mol Model 2012 18 2907 2916
18. Lipoic acid synthase (LASY): a novel role in inflammation, mitochondrial function, and insulin resistance. Padmalayam I, Hasham S, Saxena U, Pillarisetti S, Diabetes 2009 58 600 608
19. Glutathionylation of α-ketoglutarate dehydrogenase: the chemical nature and relative susceptibility of the cofactor lipoic acid to modification. McLain AL, Cormier PJ, Kinter M, Szweda LI, Free Radic Biol Med 2013 61C 161 169
20. Protein-protein interactions in assembly of lipoic acid on the 2-oxoacid dehydrogenases of aerobic metabolism. Hassan BH, Cronan JE, J Biol Chem 2011 286 8263 8276
21. R-alpha-lipoic acid action on cell redox status, the insulin receptor, and glucose uptake in 3T3-L1 adipocytes. Moini H, Tirosh O, Park YC, Cho KJ, Packer L, Arch Biochem Biophys 2002 397 2 384 391
22. Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery. A-Vadlapudi AD, Vadlapatla RK, Mitra AK, Curr Drug Targets 2012 13 994 1003
23. Lipoic and dihydrolipoic acids as antioxidants. A critical evaluation. Scott BC, Aruoma OI, Evans PJ, O'Neill C, Van der Vliet A, Cross CE, Tritschler H, Halliwell B, Free Radic Res 1994 20 2 119 133
24. Alpha-lipoic acid as a biological antioxidant. Packer L, Witt EH, Tritschler HJ, Free Rad Biol Med 1995 19 2 227 250
25. Peroxynitrite reaction with the reduced and the oxidized forms of lipoic acid: new insights into the reaction of peroxynitrite with thiols. Trujillo M, Radi R, Arch of Biochem and Biophys 2002 397 1 91 98
26. A method for measuring nitric oxide radical scavenging activity. Scavenging properties of sulfur-containing compounds. Vriesman MF, Haenen GR, Westerveld GJ, Paquay JB, Voss HP, Bast A, Pharm World Sci 1997 19 6 283 286
27. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Suzuki YJ, Tsuchiya M, Packer L, Free Radic Res Commun 1991 15 5 255 263
28. Antioxidant activities of dihydrolipoic acid and its structural homologues. Suzuki YJ, Tsuchiya M, Packer L, Free Radic Res Commun 1993 18 2 115 122
29. Singlet oxygen induced single-strand breaks in plasmid pBR322 DNA: the enhancing effect of thiols. Devasagayam TP, Di Mascio P, Kaiser S, Sies H, Biochim Biophys Acta 1991 1088 3 409 412
30. Dihydrolipoic acid-a universal antioxidant both in the membrane and in the aqueous phase. Reduction of peroxyl, ascorbyl and chromanoxyl radicals. Kagan VE, Shvedova A, Serbinova E, Khan S, Swanson C, Powell R, Packer L, Biochem Pharmacol 1992 44 8 1637 1649
31. Scavenging of hypochlorous acid by lipoic acid. Haenen GR, Bast A, Biochem Pharmacol 1991 42 11 2244 2246
32. Reactive oxygen and nitrogen species generation, antioxidant defenses, and β-cell function: a critical role for amino acids. Newsholme P, Rebelato E, Abdulkader F, Krause M, Carpinelli A, Curi R, J Endocrinol 2012 214 1 11 20
33. Protective effect of lipoic acid against oxidative stress is mediated by Keap1/Nrf2-dependent heme oxygenase-1 induction in the RGC-5 cellline. Koriyama Y, Nakayama Y, Matsugo S, Kato S, Brain Res 2013 1499 145 157
34. Circadian rythms connections to oxidative stress: implications for human health. Wilking M, Ndiaye M, Mukhtar H, Ahmad N, Antioxid Redox Signal 2013 19 192 208
35. Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. Dicter N, Madar Z, Tirosh O, J Nutr 2002 132 10 3001 3006
36. Direct and indirect antioxidant properties of α -lipoic acid. Rouchette L, Ghibu S, Richard C, Zeller M, Cottin Y, Vergely C, Mol Nutr Food Res 2013 57 114 125
37. Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid. Moini H, Packer L, Saris N-E, Toxicol Appl Pharmacol 2002 182 84 90
38. keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Zhang DD, Lo S-C, Cross JV, Templeton DJ, Hannink M, Mol Cell Biol 2004 24 10941 10953
39. Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Dinkova-kostova AT, Talalay P, Mol Nutr Food Res 2008 52 128 S138
40. Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Frizzell N, Baynes JW, Future Med Chem 2013 5 10 1075 1078
41. Thioctic (lipoic acid): a therapeutical metal-chelating antioxidant? Ou P, Tritscheler HJ, Wolff SP, Biochem Pharmacol 1995 50 123 126
42. Lipoic acid: a multifunctional antioxidant. Bast A, Haenen GR, Biofactors 2003 17 1-4 207 213
43. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM, Curr Med Chem 2004 11 9 1135 1146
44. Engagement of the insulin-sensitive pathway in the stimulation of glucose transport by alpha-lipoic acid in 3T3-L1 adipocytes. Yaworsky K, Somwar R, Ramlal T, Tritschler HJ, Klip A, Diabetologia 2000 43 3 294 303
45. Stimulation of glucose uptake by the natural coenzyme alpha-lipoic acid/thioctic acid: participation of elements of the insulin signaling pathway. Estrada DE, Ewart HS, Tsakiridis T, Volchuk A, Ramlal T, Tritschler H, Klip A, Diabetes 1996 45 12 1798 1804
46. Stimulation by alpha-lipoic acid of glucose transport activity in skeletal muscle of lean and obese Zucker rats. Henriksen EJ, Jacob S, Streeper RS, Fogt DL, Hokama JY, Tritschler HJ, Life Sci 1997 61 8 805 812
47. Therapeutical potential of inhibition of the NFkb pathway in the treatment of inflammation and cancer. Yamamoto Y, Gaynor RB, J Clin Invest 2001 107 2 135 142
48. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. El-Osta A, Brasacchio D, Yao D, Pocai A, Jones PL, Roeder RG, Cooper ME, Brownlee M, J Exp Med 2008 205 10 2409 2417
49. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Bierhaus A, Chevion S, Chevion M, Hofmann M, Quehenberger P, Illmer T, Luther T, Berentshtein E, Tritschler H, Müller M, Wahl P, Ziegler R, Nawroth PP, Diabetes 1997 46 9 1481 1490
50. Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function. Ying Z, Kampfrath T, Sun Q, Parthasarathy S, Rajagopalan S, Inflamm Res 2011 60 3 219 225
51. Physical activity and alpha-lipoic acid modulate inflammatory response through changes in thiol redox status. Zembron-Lacny A, Gajeswski M, Naczac M, Dziewiecka H, Siatkkowski I, J Physiolo 2013 69 397 404
52. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Sola S, Mir MQ, Cheema FA, Khan-Merchant N, Menon RG, Parthasarathy S, Khan BV, Circulation 2005 111 3 343 348
53. AMPK in health and disease. Steinberg GR, Kemp BE, Physiol Rev 2009 89 3 1025 1078
54. Role of AMP-activated protein kinase in mechanism of metformin action. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE, J Clin Invest 2001 108 8 1167 1174
55. Ca2+/calmodulin-dependent protein kinase kinase is involved in AMP-activated protein kinase activation by alpha-lipoic acid in C2C12 myotubes. Shen QW, Zhu MJ, Tong J, Ren J, Du M, Am J Physiol Cell Physiol 2007 293 4 1395 C1403
56. Alpha-Lipoic acid increases energy expenditure by enhancing adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor-gamma coactivator-1alpha signaling in the skeletal muscle of aged mice. Wang Y, Li X, Guo Y, Chan L, Guan X, Metabolism 2010 59 7 967 976
57. Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Targonsky ED, Dai F, Koshkin V, Karaman GT, Gyulkhandanyan AV, Zhang Y, Chan CB, Wheeler MB, Diabetologia 2006 49 7 1587 1598
58. Alpha-lipoic acid treatment reverses 2-deoxy-D-ribose-induced oxidative damage and suppression of insulin expression in pancreatic β-cells. Koh G, Yang EJ, Kim MK, Lee SA, Lee DH, Biol Pharm Bull 2013 [Epub ahead of print]. doi:10.12478/bpb.13-00292
59. AMP-activated protein kinase (AMPK) and energy sensing in the brain. Ramamurthy S, Ronnet G, Exp Neurobiol 2012 21 2 52 60
60. The AMP activated protein kinase prevents ceramide synthesis de novo and astrocytes. Blazquez C, Geelen MJ, Velasco G, Guzmán M, FEBS Lett 2001 489 2-3 149 153
61. Activation of AMO-activated protein kinase by tributyltin induces neuronal cell death. Nakatsu Y, Kotake Y, Hino A, Ohta S, Toxicol Appl Pharmacol 2008 230 3 358 363
62. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, Yun JY, Namgoong IS, Ha J, Park IS, Lee IK, Viollet B, Youn JH, Lee HK, Lee KU, Nat Med 2004 10 7 727 733
63. α lipoic acid reduced weight gain and improved lipid profile in rats fed with high fat diet. Seo EY, Ha AW, Kim WK, Nutr Res Pract 2012 6 195 200
64. Brain activity of thioctic acid enantiomers: in vitro and in vivo studies in an animal model of cerebrovascular injury. Tomassoni D, Amenta F, Amantini C, Farfariello V, Di Cesare ML, Nwankwo IE, Marini C, Tayebati SK, Int J Mol Sci 2013 14 3 4580 4595
65. Alpha-lipoic acid inhibits adipocyte differentiation by regulating pro-adipogenic transcription factors via mitogen-activated protein kinase pathways. Cho KJ, Moon HE, Moini H, Packer L, Yoon DY, Chung AS, J Biol Chem 2003 278 37 34823 34833
66. Protective effect of α-lipoic acid on islet cells co-cultured with 3T3L1 adipocytes. Wang Y, Dong W, Ding X, Wang F, Wang Y, Chen X, Yu L, Li X, Zhang A, Peng Y, Exp Ther Med 2012 4 3 469 474
67. Lipoic acid suppresses portal endotoxemia-induced steatohepatitis and pancreatic inflammation in rats. Tian YF, He CT, Chen YT, Hsieh PS, World J Gastroenterol 2013 19 18 2761 2771
68. The effect of alpha-lipoic acid on mitochondrial superoxide and glucocorticoid-induced hypertension. Ong SL, Vohra H, Zhang Y, Sutton M, Whitworth JA, Oxid Med Cell Longev 2013 2013 517045 doi:10.1155/2013/517045. Epub 2013 Feb 26
69. Cardiac fibrosis and dysfunctionin experimental diabetic cardiomyopathy are amelioreted by alpha-lipoic acid. Li CJ, Lv L, Li H, Yu D, Cardiovasc Diabetol 2012 11 142 doi:10.1186/1475-2840-11-142
70. α-Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. Deng C, Sun Z, Tong G, Yi W, Ma L, Zhao B, Cheng L, Zhang J, Cao F, Yi D, PLoS One 2013 8 3 58371
71. α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy. Yi X, Nickeleit V, James LR, Maeda N, J Diabetes Complications 2011 25 3 193 201
72. α-Lipoic acid antioxidant treatment limits glaucoma-related retinal ganglion cell death and dysfunction. Inman DM, Lambert WS, Calkins DJ, Horner PJ, PLoS One 2013 8 6 65389
73. Pyruvate Dehydrogenase Kinases in the nervous system: their principal functions in Neuronal-glial metabolic interaction and Neuro-metabolic disorders. Jha MK, Jeon S, Suk K, Curr Neuropharmacol 2012 10 393 403
74. Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities. Carvalho C, Cardoso S, Correia SC, Santos RX, Santos MS, Baldeiras I, Oliveira CR, Moreira PI, Diabetes 2012 61 5 1234 1242
75. Metabolic links between diabetes and Alzheimer's disease. Maher PA, Schubert DR, Expert Rev Neurother 2009 9 617 630
76. Progress in the development of new drugs in Alzheimer's disease. Piau A, Nourhashémi F, Hein C, Caillaud C, Vellas B, J Nutr Health Aging 2011 15 1 45 57
77. Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. Sancheti H, Akopian G, Yin F, Brinton RD, Walsh JP, Cadenas E, PLoS One 2013 8 69830
78. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Gupta A, Bisht B, Dey CS, Neuropharmacology 2011 60 6 910 920
79. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Maczurek A, Hager K, Kenklies M, Sharman M, Martins R, Engel J, Carlson DA, Münch G, Adv Drug Deliv Rev 2008 60 1463 1470
80. Alpha-lipoic acid as a new treatment option for Alzheimer's disease-a 48 months follow-up analysis. Hager K, Kenklies M, McAfoose J, Engel J, Münch G, J Neural Transm Suppl 2007 72 189 193
81. The combination of exercise training and alpha-lipoic acid treatment has therapeutic effects on the pathogenic phenotypes of Alzheimer's disease in NSE/APPsw-transgenic mice. Cho JY, Um HS, Kang EB, Cho IH, Kim CH, Cho JS, Hwang DY, Int J Mol Med 2010 25 3 337 346
82. Effects of lipoic acid on AMPK and adiponectin in adipose tissue of low- and high-fat-fed rats. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Alfredo Martínez J, Moreno-Aliaga MJ, Eur J Nutr 2013 52 2 779 787
83. Lipoic acid attenuates innate immune infiltration and activation in the visceral adipose tissue of obese insulin resistant mice. Deiuliis JA, Kampfrath T, Ying Z, Maiseyeu A, Rajagopalan S, Lipids 2011 46 1021 1032
84. Modulating an oxidative-inflmmatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function. Lamb RE, Goldstein BJ, Int J Clin Pract 2008 62 7 1087 1095
85. Short-term oral α-lipoic acid does not prevent lipid-induced dysregulation of glucose homeostasis in obese and overweight nondiabetic men. Xiao C, Giacca A, Lewis GF, Am J Physiol Endocrinol Metab 2011 301 736 E741
86. Amelioration of lipid abnormalities by α-lipoic acid through antioxidative and anti-inflammatory effects. Zhang Y, Han P, Wu N, He B, Lu Y, Li S, Liu Y, Zhao S, Liu L, Li Y, Obesity (Silver Spring) 2011 19 8 1647 1653
87. Effects of alpha-lipoic acid on body weight in obese subjects. Koh EH, Lee WJ, Lee SA, Kim EH, Cho EH, Jeong E, Kim DW, Kim MS, Park JY, Park KG, Lee HJ, Lee IK, Lim S, Jang HC, Lee KH, Lee KU, Am J Med 2011 124 85.e1 85.e8
88. An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes. Ratliff JC, Palmese LB, Reutenauer EL, Tek C, Clin Schizophr Relat Psychoses 2013 7 1 13 Jose516 @ hotmail.com
89. Sibutramine: a review of clinical efficacy. Lean MEJ, In J Obes 1997 21 30S 36S
90. The epidemiology of nonalcoolic faty liver disease: a global perspective. Lazo M, Clark JM, Semin Liver Dis 2008 28 339 350
91. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Dixon JB, Bhathal PS, O'Brien PE, Gastroenterology 2001 121 1 91 100
92. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA, J Nutr Biochem 2012 23 12 1676 1684
93. α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats. Jung TS, Kim SK, Shin HJ, Jeon BT, Hahm JR, Roh GS, Liver Int 2012 32 1565 1573
94. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA, Obesity 2012 20 10 1974 1983
95. α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Chen WL, Kang CH, Wang SG, Lee HM, Diabetologia 2012 55 6 1824 1835
96. SIRT1: new avenues of discovery for disorders of oxidative stress. Chong ZZ, Shang YC, Wang S, Maiesse K, Expert Opin Ther Targets 2012 16 167 178
97. Burning mouth syndrome. Gurvits GE, Tan A, World J Gastroenterol 2013 7 665 672
98. Alpha lipoic acid in burning mouth syndrome-a randomized double-blind placebo-controlled trial. Cavalcanti DR, da Silveira FR, J Oral Pathol Med 2009 38 254 261
99. Burning mouth syndrome and burning mouth in hypothyroidism: proposal for a diagnostic and therapeutic protocol. Femiano F, Lanza A, Buonaiuto C, Gombos F, Nunziata M, Cuccurullo L, Cirillo N, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008 105 22 e27
100. Burning mouth syndrome (BMS): an open trial of comparative efficacy of alpha-lipoic acid (thioctic acid) with other therapies. Femiano F, Minerva Stomatol 2002 51 405 409
101. Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. Hu G, Jousilhati P, Qiao Q, Katoh S, Diabetologia 2005 48 856 861
102. Biochemistry and molecular cell biology of diabetic complications. Brownlee M, Nature 2001 414 813 820
103. Antioxidant vitamin supplements and cardiovascular disease. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg D, Witztum JL, Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism, Circulation 2004 110 5 637 641
104. Effect of combined treatment with alpha-Lipoic acid and acetyl-L-carnitine on vascular function and blood pressure in patients with coronary artery disease. McMackin CJ, Widlansky ME, Hamburg NM, Huang AL, Weller S, Holbrook M, Gokce N, Hagen TM, Keaney JF Jr, Vita JA, J Clin Hypertens (Greenwich) 2007 9 4 249 255
105. Alpha lipoic acid and its antioxidant against cancer and diseases of central sensitization. Durand M, Mach N, Nutr Hosp 2013 28 1031 1038
106. α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K, Cancer Lett 2013 335 2 472 478
107. Lipoic acid inhibits cell proliferation of tumor cells in vitro and in vivo. Feuerecker B, Pirsig S, Seidl C, Aichler M, Feuchtinger A, Bruchelt G, Senekowitsch-Schmidtke R, Cancer Biol Ther 2012 13 14 1425 1435
108. Induction of ER stress-mediated apoptosis by α-Lipoic Acid in A549 cell lines. Kim JI, Cho SR, Lee CM, Park ES, Kim KN, Kim HC, Lee HY, Korean J Thorac Cardiovasc Surg 2012 45 1 1 10
109. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Free Radic Res 2003 37 2 213 223
110. Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Guais A, Baronzio G, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M, Invest New Drugs 2012 30 200 211
111. Alpha-lipoic acid as a directly binding activator of the insulin receptor: protection from hepatocyte apoptosis. Diesel B, Kulhanek-Heinze S, Höltje M, Brandt B, Höltje HD, Vollmar AM, Kiemer AK, Biochemistry 2007 46 8 2146 2155
112. The effect of alpha-lipoic acid in ovariectomy and inflammation-mediated osteoporosis on the skeletal status of rat bone. Polat B, Halici Z, Cadirci E, Albayrak A, Karakus E, Bayir Y, Bilen H, Sahin A, Yuksel TN, Eur J Pharmacol 2013 doi:S0014-2999 (13)00555 -4. 10.1016
113. Lipoic acid increases the expression of genes involved in bone formation in mice fed a high-fat diet. Xiao Y, Cui J, Shi Y, Le G, Nutr Res 2011 31 4 309 317
114. Diabetes trends in the USA. Skyler J, Oddo C, Diabetes Metab Res Ver 2002 18 21 S26
115. Global prevalences of diabetes, estimates for the year 2000 and projections for 2030. Wild S, Roglic G, Green A, Sicree R, King H, Diabetes Care 2004 27 1047 1053
116. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Study Research Group, N Eng J Med 1993 329 977 986
117. Intensive diabetes treatment and cardiovascular disease in patients with diabetes type 1. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group, N Engl J Med 2005 353 2643 2653
118. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Stratton IM, Adler AI, Neil AW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, on behalf of the UK Prospective Diabetes Study Group, BMJ 2000 321 405 412
119. Economic status and clinical care in young type 1 diabetes patients: a nationwide multicenter study in Brazil. Gomes MB, de Mattos Matheus AS, Calliari LE, Luescher JL, Manna TD, Savoldelli RD, Cobas RA, Coelho WS, Tschiedel B, Ramos AJ, Fonseca RM, Araujo NB, Almeida HG, Melo NH, Jezini DL, Negrato CA, Acta Diabetol 2013 50 5 743 752 Epub 2012 Jun 12
120. Prevalence of type 2 diabetic patients within the targets of care guidelines in daily clinical practice: a multicenter study in Brazil. Gomes MB, Giannella-Neto D, Faria M, Tambascia MA, Fonseca RM, Rea RR, Macedo G, Modesto Filho J, Schmid H, Bittencourt AV, Cavalcanti S, Rassi N, Pedrosa H, Atala Dib S, Rev Diabet Stud 2006 3 82 87
121. Economic costs of diabetes in the US in 2007. American Diabetes Association, Diabetes Care 2008 31 596 615
122. The cost of type 1 diabetes: a nationwide multicentre study in Brazil. Cobas RA, Ferraz MB, Matheus ASM, Tannus LRM, Negrato CA, Araújo LA, Dib SA, Gomes MB, Brazilian Type 1 Diabetes Study Group, Bull World Health Organ 2013 91 434 440
123. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Ceriello A, Sudhesh K, Piconi L, Esposito K, Giugliano D, Diabetes Care 2007 30 3 649 654
124. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ, Diabetes Care 2003 26 5 1374 1379
125. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Gomes MB, Cobas RA, Nunes E, Castro-Faria-Neto HC, da Matta MF, Neves R, Diabetes Res Clin Pract 2009 85 61 68
126. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR, Circulation 1999 100 10 1134 1146
127. Overweight is highly prevalent in children with type 1 diabetes and associates with cardiometabolic Risk. van Vliet M, Van der Heyden JC, Diamant M, Von Rosenstiel IA, Schindhelm RK, Aanstoot HJ, Veeze HJ, J Pediatr 2010 156 6 923 929
128. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Evans JL, Goldfine ID, Maddux BA, Grodsky GM, Diabetes 2003 52 1 1 8
129. The role of oxidative stress in the pathogenesis of type 2 diabetes: from molecular mechanism to clinical implication. Chang YC, Chuang LM, Am J Transl Res 2010 2 3 316 331
130. Advanced glycation end- products: a review. Singh R, Barden A, Mori T, Beilin L, Diabetologia 2001 44 2 129 146
131. Oxidative stress and diabetic vascular complications. Giugliano D, Ceriello A, Paolisso G, Diabetes Care 1996 19 3 257 267
132. Glucose and diabetic vascular disease. Ruderman NB, Williamson JR, Brownlee M, FASEB J 1992 6 11 2905 2914
133. 15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. Di Mario U, Pugliese G, Diabetologia 2001 44 6 674 692
134. Study of comparative effects of antioxidants on insulin sensitivity in type 2 diabetes mellitus. Udupa AS, Nahar PS, Shah SH, Kshirsagar MJ, Ghongane BB, J Clin Diagn Res 2012 6 9 1469 1473
135. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha- lipoic acid: a randomized double-blinded placebo-controlled study. Porasuphatana S, Suddee S, Nartnampong A, Konsil J, Harnwong B, Santaweesuk A, Asia Pac J Clin Nutr 2012 21 1 12 21
136. The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. de Oliveira AM, Rondó PH, Luzia LA, D'Abronzo FH, Illison VK, Diabetes Res Clin Pract 2011 92 2 253 260
137. Role of mitochondria biogenesis in the metabolic memory associated with the continued progression of diabetic retinopathy and its regulation by lipoic acid. Santos JM, Kowluru RA, Invest Ophthalmol Vis Sci 2011 52 12 8791 8798
138. Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Lin J, Bierhaus A, Bugert P, Dietrich N, Feng Y, Vom Hagen F, Nawroth P, Brownlee M, Hammes HP, Diabetologia 2006 49 5 1089 1096
139. Alpha-lipoic acid for the prevention of diabetic macular edema. Haritoglou C, Gerss J, Hammes HP, Kampik A, Ulbig MW, RETIPON Study Group, Ophthalmologica 2011 226 3 127 137
140. Oxidative stress in preretinopathic diabetes subjects and antioxidants. Nebbioso M, Federici M, Rusciano D, Evangelista M, Pescosolido N, Diabetes Technol Ther 2012 14 3 257 263
141. Reduced expression of lipoic acid synthase accelerates diabetic nephropathy. Yi X, Xu L, Hiller S, Kim HS, Nickeleit V, James LR, Maeda N, J Am Soc Nephrol 2012 23 1 103 111
142. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C, Kidney Int 2005 67 4 1371 1380
143. alpha- Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Borcea V, Nourooz-Zadeh J, Wolff SP, Klevesath M, Hofmann M, Urich H, Wahl P, Ziegler R, Tritschler H, Halliwell B, Nawroth PP, Free Radic Biol Med 1999 26 11-12 1495 1500
144. Use of alpha-lipoic acid in prevention of contrast- induced nephropathy in diabetic patients. Cicek M, Yildirir A, Okyay K, Yazici AC, Aydinalp A, Kanyilmaz S, Muderrisoglu H, Ren Fail 2013 35 5 748 753
145. Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study. Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU, Kim SB, Park JS, Am J Nephrol 2007 27 1 70 74
146. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Morcos M, Borcea V, Isermann B, Gehrke S, Ehret T, Henkels M, Schiekofer S, Hofmann M, Amiral J, Tritschler H, Ziegler R, Wahl P, Nawroth PP, Diabetes Res Clin Pract 2001 52 3 175 183
147. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Heinisch BB, Francesconi M, Mittermayer F, Schaller G, Gouya G, Wolzt M, Pleiner J, Eur J Clin Invest 2010 40 2 148 154
148. Topical treatment with anti-oxidants and Au nanoparticles promote healing of diabetic wound through receptor for advance glycation end-products. Chen SA, Chen HM, Yao YD, Hung CF, Tu CS, Liang YJ, Eur J Pharm Sci 2012 47 5 875 883
149. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G, Diabetes Care 1997 20 3 369 373
150. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Pop-Busui R, Stevens MJ, Raffel DM, White EA, Mehta M, Plunkett CD, Brown MB, Feldman EL, Diabetologia 2013 56 8 1835 1844
151. Diagnosis and mangement of diabetic peripheral neuropathy. Ziegler D, Diabet Med 1996 13 suppl 1 34 S38
152. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Dyck PJ, Davies JL, Litchy WJ, O'Brien PC, Neurology 1997 49 1 229 239
153. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA, Diabetologia 1995 38 12 1425 1433
154. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Reljanovic M, Reichel G, Rett K, Lobisch M, Schuette K, Möller W, Tritschler HJ, Mehnert H, Free Radic Res 1999 31 3 171 179
155. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R, Diabetes Care 1999 22 8 1296 1301
156. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Ruhnau KJ, Meissner HP, Finn JR, Reljanovic M, Lobisch M, Schütte K, Nehrdich D, Tritschler HJ, Mehnert H, Ziegler D, Diabet Med 1999 16 12 1040 1043
157. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, Low PA, Nehrdich D, Novosadova M, O'Brien PC, Reljanovic M, Samigullin R, Schuette K, Strokov I, Tritschler HJ, Wessel K, Yakhno N, Ziegler D, SYDNEY Trial Study Group, Diabetes Care 2003 26 3 770 776
158. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R, Diabetes Care 2006 29 11 2365 2370
159. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ, Diabetes Care 2011 34 9 2054 2060
160. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA, Diabet Med 2004 21 2 114 121
161. Alpha lipoic acid for symptomatic neuropathy in patients with diabetes: A meta-analysis of randomized controlled trials. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ, Int J Endocrinol 2012 2012 456279 doi:10.1155/2012/456279
162. Combination of alpha lipoic acid and superoxide dismutase leads to physiological and symptomatic improvements in diabetic neuropathy. Bertolloto F, Massome A, Drugs 2012 12 29 34
163. Efficacy and safety of methylcobalamin, alpha lipoic acid and pregabalin combination versus pregabalin monotherapy in improving pain and nerve conduction velocity in type 2 diabetes associated impaired peripheral neuropathic condition. Results of a pilot study. Vasudevan D, Naik MM, Mukaddam QI, Ann Indian Acad Neurol 2014 17 19 24 doi:10.4103/0972-2327.128535
164. A study of the use of carbamazepine, pregabalin and alpha lipoic acid in patients of diabetic neuropathy. Patel N, Mishra V, Patel P, Dikshot RK, J Diabetes Metab Disord 2014 13 62
165. Insulin autoimmune syndrome induced by α lipoic acid in a Caucasian woman: case report. Bresciani E, Busi A, Bazzigaluppi E, Balestere G, Diabetes Care 2011 34 146
166. Glucose-induced endoplasmic reticulum stress is independent of oxidative stress: a mechanistic explanation for the failure of antioxidant therapy in diabetes. Mooradian AD, Haas MJ, Free Radic Biol Med 2011 50 1140 1143